![Bob the Grumpy Med Chemist Profile](https://pbs.twimg.com/profile_images/1399442816623853568/uIHiI58R_x96.jpg)
Bob the Grumpy Med Chemist
@med_chemist
Followers
4K
Following
1K
Statuses
2K
Jaded. Let me know when one of you figures out how the human body works.
Armchair
Joined May 2021
@raffcolo @ducholab @KRHornberger Indeed! I've always thought that this must really irk professors who spend a lot of time teaching 1st year chemistry undergrads significant figures, and then turn around to read the literature full of grad students and PhDs constantly butchering the rules
1
0
2
@BagPhos Could you please clarify how I obtain the solvent named "obvious to those skilled in the art" :)
1
0
4
I've previously collected similar articles with useful warnings and tips about methods such as scavenger reagents. See them by following the linked threaded tweets
Glad there is room for papers like this to be published. I hope there will be some follow up on the original ACS Med. Chem. Lett. paper on the supposed probe. Some other references on metal impurities linked below, if useful.
0
0
1
@AdamQuic Happy to. @KRHornberger has provided some great resources around PK reporting, such as the thread below Regarding the nature paper, the issues are unfortunately beyond lack of data, and show a misunderstanding of the usual meaning of the parameters.
🧵PSA: we need to chat about pharmacokinetics & pubs. If you plan to publish in vivo PD/efficacy studies, the minimum credible accompanying PK package is an IV leg + an IP/PO leg if that's your eventual route. In the same species, preferably at the planned efficacy dose. 1/
1
0
0
@thederzzz @KRHornberger Regarding the paper with the odd PK table in my original post, some of the parameters mentioned do not match their usual definitions.
0
0
2
On the other hand, the efficacy data for antibiotics does mitigate the risk of mischaracterization a bit. Paws up / paws down is a pretty clear endpoint!
I propose a solution to 2 problems: - Lack of novel antibiotics - Abundance of terrible in vivo efficacy studies Solution: If you publish a bad efficacy study, you must instead work on antibiotics development, where output of animal model is much clearer... paws up / paws down
0
0
1
@VRBoombatzMDPhD @KRHornberger @D_B_McConnell @agwaterson Right, fair point that it’s definitely a simplification, but at least clarifies that you can’t win the game simply by moving the PK curve higher and higher, and brings the idea of a therapeutic window into focus.
1
0
2